Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.

@article{Stansfield2013BosutinibAS,
  title={Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.},
  author={Lindsay Stansfield and Thomas E Hughes and Tracey L Walsh-Chocolaad},
  journal={The Annals of pharmacotherapy},
  year={2013},
  volume={47 12},
  pages={1703-11}
}
OBJECTIVE To review clinical trials and main characteristics of bosutinib, a second-generation tyrosine kinase inhibitor (TKI) for treatment of chronic myelogenous leukemia (CML). DATA SOURCES Pertinent data were identified through a search of PubMed (January 1990-April 2013) using the primary search terms SKI-606, bosutinib, and CML. Additionally, preliminary reports published in abstract form by the American Society of Clinical Oncology and American Society of Hematology (January 1990-April… CONTINUE READING